Compare ENTA & MLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTA | MLAB |
|---|---|---|
| Founded | 1995 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.3M | 489.8M |
| IPO Year | 2012 | 1995 |
| Metric | ENTA | MLAB |
|---|---|---|
| Price | $14.10 | $80.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | $20.40 | ★ $94.00 |
| AVG Volume (30 Days) | ★ 159.1K | 97.1K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.79% |
| EPS Growth | 29.93 | ★ 99.24 |
| EPS | N/A | ★ 1.95 |
| Revenue | ★ $102,814,000.00 | N/A |
| Revenue This Year | $5.91 | $6.07 |
| Revenue Next Year | N/A | $5.41 |
| P/E Ratio | ★ N/A | $41.33 |
| Revenue Growth | ★ 16.48 | N/A |
| 52 Week Low | $4.09 | $59.63 |
| 52 Week High | $17.15 | $130.12 |
| Indicator | ENTA | MLAB |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 38.46 |
| Support Level | $13.39 | $77.23 |
| Resistance Level | $15.52 | $81.62 |
| Average True Range (ATR) | 0.83 | 4.18 |
| MACD | -0.05 | -1.95 |
| Stochastic Oscillator | 43.23 | 36.78 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.